Mechanistically, we found that TAZ promoted cell proliferation and tumor formation of GBM cells by potentiating the EGFR/AKT/ERK pathway, whereas all the effects were blocked by the EGFR inhibitor Erlotinib. This evidence concerns the gene EGFR and neoplasm.